Skip to content
Peptigraph home

Peptides for Blood pressure

The peptides people most often research for blood pressure, with how much evidence exists for each. A long list does not mean any of them is proven to work in people.

Medically reviewed by Juan Pablo Frías, MD · · DisclosureUpdated
Peptides listed
6
With human trials
4
FDA approved (any use)
3
Showing 6 peptides · ordered by search interest for this goal
  1. TirzepatideGLP-1 / GIP dual agonistHuman RCT evidence, 4 of 4The New England journal of medicine 2025, PMID 41406444Human143Animal2Summarised7FDA approved (Mounjaro, Zepbound)For blood pressureOverview
  2. BPC-157Gastric pentadecapeptideAnimal evidence, 2 of 4Biomedicines 2022, PMID 35203478Human0Animal7Summarised1PCAC voted 8–6 for 503A (Jul 2026)For blood pressureOverview
  3. RetatrutideGLP-1 / GIP / glucagon triple agonistHuman RCT evidence, 4 of 4Diabetes, obesity & metabolism 2026, PMID 42608321Human9Animal0Summarised3Investigational · phase 3For blood pressureOverview
  4. SemaglutideGLP-1 agonistHuman RCT evidence, 4 of 4American heart journal 2025, PMID 40345413Human269Animal5Summarised8FDA approved (Ozempic, Wegovy, Rybelsus)For blood pressureOverview
  5. HGHRecombinant growth hormoneHuman RCT evidence, 4 of 4Clinical endocrinology 1998, PMID 10197085Human324Animal16Summarised4FDA approved (prescription only)For blood pressureOverview
  6. IpamorelinGHRP (ghrelin receptor agonist)No study with an outcome for blood pressurePubMed search, 11 Oct 2026Human0Animal0Summarised0Not FDA approved · research chemicalOverview
Read this first

What this list does not show

Search demand tells you what people are curious about, not what works. Read each peptide's evidence before anything else.

Search interest is not evidence

This list follows what people search for and discuss. It says nothing about how well any peptide works.

Animal results may not carry over

Doses, routes and effects seen in rodents or cell dishes often have no tested human equivalent.

Approval covers specific uses

An FDA approval applies to the conditions and doses on the label, not to every goal a drug is searched with.

Combinations are a separate question

Blends and stacks put several peptides together. Evidence for one peptide is not evidence for the mix.

What blood pressure measures

MedlinePlus defines blood pressure as the force of blood pushing against the walls of the arteries.[9]

It says high blood pressure usually has no symptoms.[9]

Blood pressure results in obesity and growth hormone trials

Semaglutide has 269 human-only papers and tirzepatide 143 that touch blood pressure, whereas BPC-157 has 7 animal papers and no human ones, and ipamorelin has none.

Calculated from source our PubMed count ledger ledger (PubMed title/abstract counts, 2026-10-02); tirzepatide human only 143, animal only 2, rct 19; bpc-157 human only 0, animal only 7, rct 0; retatrutide human only 9, animal only 0, rct 0; semaglutide human only 269, animal only 5, rct 30; hgh human only 324, animal only 16, rct 65; ipamorelin human only 0, animal only 0, rct 0. Formula: Counts copied from each peptide ledger: humanOnly = human studies not also tagged animal, animalOnly = animal studies not tagged human, rct = human randomised trials. They count papers mentioning the topic, not positive results.

In a tirzepatide trial, the net reduction by 72 weeks versus placebo was 6.8 mm Hg systolic and 4.2 mm Hg diastolic.[10]

A mediation analysis of that trial indicated that weight loss explained 68% of the systolic and 71% of the diastolic reduction.[10]

In a phase 3 CagriSema trial, week-68 systolic pressure changed by -10.9 versus -2.8 mm Hg on placebo, and diastolic by -5.4 versus -1.7 mm Hg.[11]

A meta-analysis of retatrutide found a significant decrease in systolic pressure.[12]

A systematic review of growth hormone found it did not consistently affect blood pressure or bone mineral density.[13]

In a semaglutide withdrawal trial, continued treatment versus placebo lowered systolic pressure by 3.9 mm Hg.[14]

Common questions

What are the best peptides for blood pressure?

In the tirzepatide mediation analysis, weight loss explained 68% of the systolic and 71% of the diastolic reduction.[10]

Is there a best peptide for blood pressure?

The cited blood pressure figures come from obesity trials, for example CagriSema's -10.9 versus -2.8 mm Hg systolic at week 68.[11]

Does BPC-157 lower blood pressure?

The ledger finds no human-only BPC-157 paper on blood pressure, only animal papers.

Calculated from bpc-157 human only 0, animal only 7, rct 0. Formula: humanOnly 0, animalOnly 7 in goals.json.

Does growth hormone affect blood pressure?

A systematic review found no consistent effect on blood pressure or bone mineral density.[13]

Sources

  1. 1Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes.The New England journal of medicine · 2025PMID 41406444Accessed 2 Oct 2026
  2. 2Stable Gastric Pentadecapeptide BPC 157 May Counteract Myocardial Infarction Induced by Isoprenaline in Rats.Biomedicines · 2022PMID 35203478Accessed 2 Oct 2026
  3. 3Retatrutide-Associated Improvements in Cardiovascular Risk Biomarkers in Adults With Obesity With or Without Type 2 Diabetes.Diabetes, obesity & metabolism · 2026PMID 42608321Accessed 2 Oct 2026
  4. 4Effect of once-weekly subcutaneous semaglutide on arterial inflammation in people with type 2 diabetes and cardiovascular disease using PET-MRI: Primary results of a randomized, double-blind, placebo-controlled trial.American heart journal · 2025PMID 40345413Accessed 2 Oct 2026
  5. 5HDL-cholesterol reductions associated with adult growth hormone replacement.Clinical endocrinology · 1998PMID 10197085Accessed 2 Oct 2026
  6. 6PubMed search: ipamorelin[tiab] (50 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  7. 7PubMed search: ipamorelin[tiab] AND (half-life[tiab] OR pharmacokinetic*[tiab]) (4 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  8. 8PubMed search: ipamorelin[tiab] AND (adverse[tiab] OR "side effect*"[tiab] OR safety[tiab] OR tolerab*[tiab] OR toxicity[tiab] OR "case report"[pt]) (11 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 11 Oct 2026
  9. 9Official web pageOfficial web page · web page
  10. 10Tirzepatide and blood pressure reduction: stratified analyses of the SURMOUNT-1 randomised controlled trial.Heart (British Cardiac Society) · 2024PMID 39084707Accessed 2 Oct 2026
  11. 11CagriSema Reduces Blood Pressure in Adults With Overweight or Obesity: REDEFINE 1.Hypertension (Dallas, Tex. : 1979) · 2026PMID 41328546Accessed 2 Oct 2026
  12. 12Effect of Retatrutide, a Novel Triple Receptor Agonist, on Blood Pressure and Lipid Levels: A Systematic Review and Meta-analysis of Randomized Controlled Trials.High blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension · 2026PMID 42371360Accessed 2 Oct 2026
  13. 13GH replacement therapy in elderly GH-deficient patients: a systematic review.European journal of endocrinology · 2011PMID 21339335Accessed 2 Oct 2026
  14. 14Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial.JAMA · 2021PMID 33755728Accessed 2 Oct 2026

Found an error? Report a correction.